Neuroscience

Viewing Page 5 of 25 | Showing Results 41 - 50 of 246

February Pet of the Month at the Multiple Sclerosis Center

February 12, 2015

Cat: Kelly Bear
Owner: Misty
Age: 4
Breed: Domestic Longhair Calico
From: Eva's Eden - Cat Rescue, Blaine, Washington
Favorite toy: Toy bird that chirps
Favorite snack: Greenies treats
Unique fact: Only female cats can be Calico
Best trick: To walk on a leash or ride in a car
Describe your pet in one word: Love
How has your pet taught you to live life?
"She has shown unconditional love and taught me to  ...

Copaxone and the Interferon Betas Are Clinically Similar

February 10, 2015
Copaxone and the interferon betas (IFN-β) are both effective treatments for a relapsing form of multiple sclerosis (MS). A new study finds that MS patients followed over 10 years have similar annualized relapse rates (ARR) whether they take Copaxone or one of the interferon betas.

This recent study looked at 10 years of data on over 3,000 RRMS patients and found that Copaxone and IFN-β were similarly successful in reducing relapses. In the new study, researchers collected data on 3,326 RRMS patients who were using either IFN-β or Copaxone as their first-ever disease-modifying therapy (DMT) for at least 6 months, and had started treatment within 10 years of their first symptom. To be included in the study, patients also had to have had at least one relapse recorded during the two years leading up to the start of their initial DMT.

The researchers looked at ...

MS Patient Enjoys Skiing Again

February 07, 2015

Bud Feuerstein is flying down the mountainside on an adaptive mono ski, a product of Outdoors For All (a nonprofit organization that enables recreational activities for individuals with disabilities).



Eight years prior, Bud would have been carving the slopes on his own set of skis, but due to a rare disease, he was left paralyzed from the chest down. Bud will never forget the night he was lying in bed and an odd sensation came over his body. Within seconds, he was paralyzed. Months later, he was diagnosed with transverse myelitis, a disease in the multiple sclerosis family. Having a better chance of winning the lottery, Bud was blindsided by this diagnosis, and his life was forever changed.

With this earth-shattering news, Bud had two fears:

Preliminary results from study of myelin repair

February 06, 2015

Results were released recently from a study of a medication that may promote myelin repair. The MS Center at Swedish was one of the research sites for this study. The medication, rHIgM22, is an antibody that encouraged myelin repair in animal models. The way that it helps with myelin repair is not known. This study was a phase I study, which means that it was the first time that this medication was used in humans. Phase I studies are done to determine the safety of a medication, and also to help determine the dose of the medication.

In this study, patients ...

Rhinoplasty Surgery in Seattle

January 29, 2015
Rhinoplasty Surgery for Seattle patients by board-certified plastic surgeon Dr. Scott Sattler at Sound Plastic Surgery

MS Book Club Launch at the Swedish Multiple Sclerosis Center

January 28, 2015
What: Book club launch, hosted by author of Chef Interrupted, Trevis Gleason

When: Friday, March 6, noon - 3 p.m.

Where: MS Center at Swedish
1600 East Jefferson Street, A Level
Seattle, WA 98122

RSVP: Mallory Higgins, 206-320-2200
 

Fall Prevention Program for Multiple Sclerosis

January 22, 2015

Falls happen.  Fall incidence can increase with disability.  Falls in multiple sclerosis (MS) are common and often occur due to motor weakness, imbalance, gait impairment, and not using the adaptive equipment (cane, walker, orthotic) designed to help one ambulate more effectively and safely.

Falls can result in injury. This injury might only be an embarrassment to one’s pride; however, at other times, falls can contribute to more serious problems such as a fractured hip, a head injury, and in the worst case scenario, death.  It is therefore important that we take a proactive approach to fall prevention.

The International Multiple Sclerosis Falls Prevention Research Network has examined the roles of various fall prevention rehabilitation programs to learn which might be the most effective in reducing fall risk and falls (click here to read the research).  A critical e...

The ABLE Act (Achieving A Better Life Experience Act) Approved by Congress: A Step in the Right Direction for Individuals with Disability

January 20, 2015
The ABLE Act, also known as The Achieving A Better Life Experience Act, was finally approved by Congress on a 76-16 vote and was signed into law by President Obama in December 2014.  Although the ABLE Act does not directly benefit individuals with disabilities acquired later in life, it is a bold first step in recognizing the financial needs of individuals with disabilities and not penalizing these individuals from receiving public benefits.

What is the ABLE Act?

The ABLE Act allows people with disabilities and their families to set up a special savings account for disability related expenses.  Earnings on an ABLE account would not be taxed.  Disability related expenses is broad in definition and includes: medical and dental care, education, community based support, personal support services, employment training, assistive technology, housing, and transportation. 

How is the ABLE Act different from existing law?...

Hematopoietic Stem Cells for Multiple Sclerosis

January 13, 2015

The MS Center at Swedish Neuroscience Institute played a major role in a research study that recently garnered national attention. This research was published in JAMA Neurology. This research investigated the effect of high dose immunosuppressive followed by hematopoietic stem cell therapy.

This therapy consists of collecting hematopoietic stem cells from patients' blood. Patients then undergo an intense course of immunosuppressive therapy with four medications. This therapy is sufficient to eliminate most of the patient’s bone marrow including white blood cells. The hematopoietic stem cells are then given back to the patient so that their bone marrow may be reconstituted. In multiple sclerosis (MS),  the immune system attacks the brain. The hope is that with this therapy the reconstituted immune system will have less of a tendency to attack the br...

Gilenya fails in primary progressive multiple sclerosis trial

December 29, 2014
We recently found out that Gilenya (fingolimod), an oral treatment for relapsing multiple sclerosis (MS), did not slow down disability progression in a phase III trial among primary progressive MS (PPMS) patients. The trial, called INFORMS, was the largest to date in PPMS, involving 970 patients in North America, Europe, and Australia. Patients were assigned to placebo or Gilenya for 3 years, and the primary outcome was a composite of walking, arm function and overall disability measures. Unfortunately, the progression rates in Gilenya and placebo groups were not statistically different. A full report of the trial will be presented at one of the upcoming neurology meetings, possibly in April 2015.